Subcellular distribution of azithromycin and clarithromycin in rat alveolar macrophages (NR8383) in Vitro

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 9, 2013, Pages 1494-1499

  Togami, Kohei ^a   Chono, Sumio ^a   Morimoto, Kazuhiro ^b  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^b TEIKYO HEISEI UNIVERSITY   (Japan)

Author keywords

Acidic organelle; Granules fraction; Intracellular accumulation; Intracellular parasitic pathogen; Macrolide antimicrobial agent

Indexed keywords

AMMONIUM CHLORIDE; AZITHROMYCIN; CLARITHROMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FRACTIONATION; CELL ORGANELLE; CELL PH; CELLULAR DISTRIBUTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOSOL; DRUG DISTRIBUTION; IN VITRO STUDY; INCUBATION TEMPERATURE; LUNG ALVEOLUS MACROPHAGE; NONHUMAN; RAT; TEMPERATURE DEPENDENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BIOLOGICAL TRANSPORT; CELL LINE; CLARITHROMYCIN; MACROPHAGES, ALVEOLAR; RATS;

EID: 84884648979     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00423     Document Type: Article

References (45)

1. Bright GM, Nagel AA, Bordner J, Desai KA, Dibrino JN, Nowakowska J, Vincent L, Watrous RM, Sciavolino FC, English AR, Retsema JA, Anderson MR, Brennan LA, Borovoy RJ, Cimochowski CR, Faiella JA, Girard AE, Girard D, Herbert C, Manousos M, Mason R. Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. J. Antibiot., 41, 1029-1047 (1988).
2. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob. Agents Chemother., 32, 1710-1719 (1988).
3. Miyashita N, Fukano H, Yoshida K, Niki Y, Matsushima T. In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae. J. Antimicrob. Chemother., 52, 497-499 (2003).
4. Sato T, Tateda K, Kimura S, Ishii Y, Yamaguchi K. In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila. Antimicrob. Agents Chemother., 55, 1594-1597 (2011).
5. Chiu LM, Menhinick AM, Johnson PW, Amsden GW. Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers. J. Antimicrob. Chemother., 50, 1075-1079 (2002).
6. Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA. Pharmacokinetic and in vivo studies with azithromycin (CP-62, 993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob. Agents Chemother., 31, 1948-1954 (1987).
7. Bosnar M, Kelneric Z, Munic V, Erakovic V, Parnham MJ. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob. Agents Chemother., 49, 2372-2377 (2005).
8. Carbon C. Clinical relevance of intracellular and extracellular concentrations of macrolides. Infection, 23 (Suppl. 1), S10-S14 (1995).
9. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob. Agents Chemother., 33, 277-282 (1989).
10. Muto C, Liu P, Chiba K, Suwa T. Pharmacokinetic-pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease. J. Antimicrob. Chemother., 66, 165-174 (2011).
11. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob. Agents Chemother., 36, 1171-1175 (1992).
12. Gordon SB, Read RC. Macrophage defences against respiratory tract infections. Br. Med. Bull., 61, 45-61 (2002).
13. Nara C, Tateda K, Matsumoto T, Ohara A, Miyazaki S, Standiford TJ, Yamaguchi K. Legionella-induced acute lung injury in the setting of hyperoxia: protective role of tumour necrosis factor-alpha. J. Med. Microbiol., 53, 727-733 (2004).
14. Yamaguchi H, Haranaga S, Widen R, Friedman H, Yamamoto Y. Chlamydia pneumoniae infection induces differentiation of monocytes into macrophages. Infect. Immun., 70, 2392-2398 (2002).
15. Mandell GL. Interaction of intraleukocytic bacteria and antibiotics. J. Clin. Invest., 52, 1673-1679 (1973).
16. Cook PJ, Andrews JM, Wise R, Honeybourne D. Distribution of cefdinir, a third generation cephalosporin antibiotic, in serum and pulmonary compartments. J. Antimicrob. Chemother., 37, 331-339 (1996).
17. Kikuchi E, Yamazaki K, Kikuchi J, Hasegawa N, Hashimoto S, Ishizaka A, Nishimura M. Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid. Respirology, 13, 221-226 (2008).
18. Nicolau DP, Sutherland C, Winget D, Baughman RP. Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. Pulm. Pharmacol. Ther., 25, 94-98 (2012).
19. Ong CT, Dandekar PK, Sutherland C, Nightingale CH, Nicolau DP. Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae. Chemotherapy, 51, 339-346 (2005).
20. Ziglam HM, Baldwin DR, Daniels I, Andrew JM, Finch RG. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother., 50, 1011-1015 (2002).
21. Briones E, Colino CI, Lanao JM. Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J. Control. Release, 125, 210-227 (2008).
22. Van Bambeke F, Barcia-Macay M, Lemaire S, Tulkens PM. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr. Opin. Drug Discov. Devel., 9, 218-230 (2006).
23. Togami K, Chono S, Morimoto K. Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages. Biopharm. Drug Dispos., 32, 389-397 (2011).
24. Togami K, Chono S, Morimoto K. Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. Pharmazie, 67, 389-393 (2012).
25. Kohno Y, Yoshida H, Suwa T, Suga T. Uptake of clarithromycin by rat lung cells. J. Antimicrob. Chemother., 26, 503-513 (1990).
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal. Biochem., 72, 248-254 (1976).
27. Togami K, Chono S, Seki T, Morimoto K. Intracellular pharmacokinetics of telithromycin, a ketolide antibiotic, in alveolar macrophages. J. Pharm. Pharmacol., 62, 71-75 (2010).
28. Seral C, Carryn S, Tulkens PM, Van Bambeke F. Influence of Pglycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J. Antimicrob. Chemother., 51, 1167-1173 (2003).
29. Moreau A, Le Vee M, Jouan E, Parmentier Y, Fardel O. Drug transporter expression in human macrophages. Fundam. Clin. Pharmacol., 25, 743-752 (2011).
30. Garver E, Hugger ED, Shearn SP, Rao A, Dawson PA, Davis CB, Han C. Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat. Drug Metab. Dispos., 36, 2492-2498 (2008).
31. Lan T, Rao A, Haywood J, Davis CB, Han C, Garver E, Dawson PA. Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides. Drug Metab. Dispos., 37, 2375-2382 (2009).
32. Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, Dorje F, Fromm MF, Konig J. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos., 35, 779-786 (2007).
33. Hand WL, Hand DL. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int. J. Antimicrob. Agents, 18, 419-425 (2001).
34. Chanteux H, Paternotte I, Mingeot-Leclercq MP, Brasseur R, Sonveaux E, Tulkens PM. Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin. Pharm. Res., 20, 624-631 (2003).
35. Poole B, Ohkuma S. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J. Cell Biol., 90, 665-669 (1981).
36. Yoshida H, Okumura K, Hori R. Contribution of monoamine oxidase (MAO) to the binding of tertiary basic drugs in isolated perfused rat lung. Pharm. Res., 7, 398-401 (1990).
37. Vestal RE, Kornhauser DM, Shand DG. Active uptake of propranolol by isolated rabbit alveolar macrophages and its inhibition by other basic amines. J. Pharmacol. Exp. Ther., 214, 106-111 (1980).
38. Ishizaki J, Yokogawa K, Hirano M, Nakashima E, Sai Y, Ohkuma S, Ohshima T, Ichimura F. Contribution of lysosomes to the subcellular distribution of basic drugs in the rat liver. Pharm. Res., 13, 902-906 (1996).
39. Barcia-Macay M, Mouaden F, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J. Antimicrob. Chemother., 61, 1288-1294 (2008).
40. Lemaire S, Tulkens PM, Van Bambeke F. Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells. studies with macrophages and polymorphonuclear neutrophils. Antimicrob. Agents Chemother., 54, 2540-2548 (2010).
41. Ishizaki J, Yokogawa K, Ichimura F, Ohkuma S. Uptake of imipramine in rat liver lysosomes in vitro and its inhibition by basic drugs. J. Pharmacol. Exp. Ther., 294, 1088-1098 (2000).
42. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta, 1151, 201-215 (1993).
43. Milatovic D. Intraphagocytic activity of erythromycin, roxithromycin and azithromycin. Eur. J. Clin. Microbiol. Infect. Dis., 9, 33-35 (1990).
44. Steinman RM, Brodie SE, Cohn ZA. Membrane flow during pinocytosis. A stereologic analysis. J. Cell Biol., 68, 665-687 (1976).
45. Togami K, Chono S, Morimoto K. Aerosol-based efficient delivery of azithromycin to alveolar macrophages for treatment of respiratory infections. Pharm. Dev. Technol., 1-5 (2012).